Company news

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) news

Amylyx Pharmaceuticals, Inc. news releases on 6ix. Latest, Oct 6, 2026: Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial…

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) news

Press releases & updates

Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting

Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum

Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference

Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock

Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026

Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results

Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026

Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026

Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation

Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S

Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial

Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results

Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences

Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results

Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025

Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025

Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences

Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome

Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results

Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences

Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025

Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer

Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference